HiCisco (002653.SZ) announced the company's riluzole oral solution EXSERVAN project (abbreviation...
Zhitong Finance App News, HiCisco (002653.SZ) announced that the company's riluzole oral solution EXSERVAN project (abbreviation: riluzole oral solution) is currently in the drug import registration review stage at the Drug Evaluation Center of the China Drug Administration. Recently, after careful consideration by the company of investment risks and future market risks in the continued development of riluzole oral dissolution membranes, in order to rationally allocate the company's commercial resources and focus on advantageous projects in the product pipeline, the company has notified the licensor Aquestive of the United States that it plans to terminate the licensing agreement with Aquestive for riluzole oral dissolution, and will stop related development and import registration work. At the same time, based on the principle of prudent accounting, the other non-current assets formed by the introduction project are fully calculated for asset impairment preparations.